Physician profile
David C Evans
NPI 1346299443
$3,234.08
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,240 · 2020: $304 · 2021: $399 · 2022: $81.75 · 2023: $667 · 2024: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,208.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $718.53 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $372.75 | 2019-2024 | |
| Lilly USA, LLC | $332.60 | 2019-2024 | Mounjaro, Zepbound |
| Amgen INC. | $312.56 | 2019-2023 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $190.94 | 2019-2022 | |
| Pfizer INC. | $183.85 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $131.30 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $114.12 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.66 | 2019-2024 | Jardiance, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.77 | 2019-2024 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $80.02 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $78.94 | 2019-2024 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $73.20 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $56.50 | 2019-2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $55.67 | 2023-2024 | Rexulti |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $33.89 | 2019-2020 | |
| Esperion Therapeutics, INC. | $30.58 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $25.36 | 2019 | |
| Genzyme Corporation | $24.46 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $23.06 | 2019-2021 | |
| Horizon Therapeutics Plc | $23.04 | 2021 | |
| Clarus Therapeutics INC. | $19.76 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $19.51 | 2021 | |
| Tris Pharma INC | $17.35 | 2024 | Dyanavel Xr |
| Cranial Technologies, INC | $15.52 | 2020 | |
| Gilead Sciences, INC. | $14.68 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.00 | 2019 | |
| Tolmar, INC. | $13.40 | 2024 | |
| Exact Sciences Corporation | $13.29 | 2024 | Cologuard Collection Kit |
| Amneal Pharmaceuticals LLC | $13.15 | 2024 | Unithroid |
| Mylan Specialty L.P. | $11.88 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.